You are now logged out.
Today’s Most Rewarding Investment Strategy
From Baltimore – “As an analyst, I love discovering great companies that are saving lives or improving lives,” says Chief Income Strategist Marc Lichtenfeld.
Despite the biotech sector’s reputation for being volatile, it’s hard to argue against innovative healthcare companies when it comes to delivering the best profits to investors.
They’ve produced better gains than just about any kind of company in the market… especially over the long term.
Just consider that Bristol Myers Squibb (NYSE: BMY) is up 1,660% since 1981… Pfizer (NYSE: PFE) is up 4,793% since 1982… and Abbott Laboratories (NYSE: ABT) is up 17,132% since 1981.
Over the past 10 years, the S&P 500 Health Care index has produced a return of more than 377%. The S&P Biotechnology Select Industry Index has seen a total return of more than 482% over that time.
For short-term gains, we need to look no further than our own biotech expert, bestselling author, Senior Editor of The Oxford Income Letter and Editor of Lightning Trend Trader, Marc Lichtenfeld.
Marc recommended Celldex Therapeutics (Nasdaq: CLDX) to Members for a 419% return over 11 months, NPS Pharmaceuticals for a 188% partial return over seven months and AbbVie (NYSE: ABBV) for an outstanding 2,381% partial return over 11 months, just to name a few.
In today’s Market Wake-Up Call, Marc joins Associate Publisher and host Rachel Gearhart to talk about the very essence of the biotech sector’s volatility and how it consistently churns out record-setting returns. Marc strongly believes that 2022 and beyond could produce even greater gains as we continue to see revolutionary new treatments and cures.
Rachel asks Marc, “Where do you see the shining light in biotech right now?” Marc responds that he likes what he sees in new cancer therapies, especially now that the U.S. Food and Drug Administration can refocus on new clinical trials in this area.
Rachel also asks Marc whether there is a play in biotech that produces a good dividend for investors. Marc explains why Members should consider his two favorite blue chip biotechs right now, as both are paying good dividends…
- AbbVie is a pharma giant that stands to grow sales from its Imbruvica drug to $8 billion in the coming year and raises its dividend every year.
- Gilead Sciences (Nasdaq: GILD) is one of Marc’s favorite companies that also truly makes a difference in lives around the world. Gilead cured hepatitis C, made HIV a manageable condition and produced the COVID-19 drug remdesivir – which is effective in reducing recovery time in adults hospitalized with the virus.
How could we not love companies that save lives, improve the well-being of millions of people and pay a dividend to boot?
This brings me to another feel-good opportunity – one you can really enjoy. Plus, you’ll learn how to make great profits at the same time…
Join me for the Club’s first Oxford Investing Games, which will be hosted by Marc. This FREE event will take place on October 27 at 1 p.m. ET, and signing up for it could be the single best thing you do for your investing success this year.
This is a free, online training. If you sign up for text alerts today, Marc will send you his special research report focused on his favorite biotech plays.
Better still, this free training is designed to be just as fun and entertaining as it is effective. It will be interactive – with great prizes!
The best prize of all? I’m certain we will all become better investors simply by participating. Just click here to register.
Enjoy your Sunday,
Julia